期刊
JOURNAL OF PARASITOLOGY
卷 95, 期 2, 页码 461-466出版社
AMER SOC PARASITOLOGISTS
DOI: 10.1645/GE-1686.1
关键词
-
类别
资金
- Research Initiative for Scientific Enhancement (RISE) Program at the University of Texas at El Paso, El Paso, Texas (UTEP)
- NSF [0245071]
- NIH/NCRR [5G12RR008124]
- Deutsche Forschungegemeinschaft [SFB544]
- NIH/MBRS/SCORE Program [2S06GM00812-37]
- National Institute of Health [2S06 GM-801233, U54 AI057156]
- Robert A. Welch Foundation
Changes disease, caused by Trypanosoma cruzi, is a widespread infection in Latin America. Currently, only 2 partially effective and highly toxic drugs, i.e., benznidazole and nifurtimox, are available for the treatment of this disease, and several efforts are underway in the search for better chemotherapeutic agents. Here, we have determined the trypanocidal activity of 2,3-diphenyl-1,4-naphthoquinone (DPNQ), a novel quinone derivative. In vitro, DPNQ was highly cytotoxic at a low, micromolar concentration (LD50 = 2.5 mu M) against epimastigote, cell-derived trypomastigote, and intracellular amastigote forms of T. cruzi, but not against mammalian cells (LD50 = 130 mu M). In vivo studies on the murine model of Chagas disease revealed that DPNQ-treated animals (3 doses of 10 mg/kg/day) showed a significant delay in parasitemia peak and higher (up to 60%) survival rate 70 days post-infection, when compared with the control group (infected, untreated). We also observed a 2-fold decrease in parasitemia between the control group (infected, untreated) and the treated group (infected, treated). No apparent drug toxicity effects were noticed in the control group (uninfected, treated). In addition, we determined that DPNQ is the first competitive inhibitor of T. cruzi lipoamide dehydrogenase (TeLipDH) thus far described. Our results indicate that DPNQ is a promising chemotherapeutic agent against T. cruzi.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据